[시장보고서]아나필락시스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

아나필락시스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Anaphylaxis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

상품코드 : 1742557

리서치사 : Transparency Market Research

발행일 : 2025년 04월

페이지 정보 : 영문 214 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,598,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,049,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,500,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

아나필락시스 시장 - 조사 범위

TMR의 조사 보고서 "세계 아나필락시스 시장"은 2025년부터 2035년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회도 조사했습니다. 이 보고서는 2019년부터 2035년까지의 세계 아나필락시스 시장의 수익과 예측을 제공하기 위해 2025년을 기준 연도로, 2035년을 예측 연도로 설정했습니다. 또한, 2025년부터 2035년까지 세계 아나필락시스 시장의 CAGR(%)도 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 아나필락시스 시장을 이해하고자 했습니다.

시장 현황
2024년 시장 규모	21억 달러
2035년 시장 규모	39억 달러
CAGR	5.9%

이 보고서는 세계 아나필락시스 시장의 경쟁 구도에 대해 자세히 연구하고 있습니다. 세계 아나필락시스 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 세계 아나필락시스 시장 기업의 속성으로서 이 보고서에서 소개됩니다.

주요 지역/국가의 의료비 지출
아나필락시스 관리의 기술 진보
주요 지역/국가의 역학
주요 지역/국가의 규제 시나리오
Porter's Five Forces 분석
PESTEL 분석
밸류체인 분석
최종사용자에 대한 주요 구입 지표
신규 시장 진입자를 위한 시장 개척 전략
주요 업계 이벤트(파트너십, 협업, 제품 승인, 합병 및 인수)
주요 경쟁사 제공 제품 벤치마크

제6장 세계의 시장 분석과 예측 : 약물 종류별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 약물 종류별, 2020-2035년
- 에피네프린
- 항히스타민제
- 기타
약물 종류별 시장 매력

제7장 세계의 시장 분석과 예측 : 제형별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 제형별, 2020-2035년
- 주사제
- 정제/캡슐
- 기타
제형별 시장 매력

제8장 세계의 시장 분석과 예측 : 투여 경로별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 투여 경로별, 2020-2035년
- 근육내 주사
- 피하주사
- 경구
- 기타
투여 경로별 시장 매력

제9장 세계의 시장 분석과 예측 : 약물 유형별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 약물 유형별, 2020-2035년
- 브랜드
- 제네릭
약물 유형별 시장 매력

제10장 세계의 시장 분석과 예측 : 유통 채널별

소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
- 병원 약국
- 소매 약국
- 온라인 약국
유통 채널별 시장 매력

제11장 세계의 시장 분석과 예측 : 지역별

주요 조사 결과
시장 금액 예측 : 지역별
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
지역별 시장 매력

제12장 북미의 시장 분석과 예측

미국
캐나다

제13장 유럽의 시장 분석과 예측

독일
영국
프랑스
스페인
이탈리아
기타 유럽

제14장 아시아태평양의 시장 분석과 예측

중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양

제15장 라틴아메리카의 시장 분석과 예측

브라질
멕시코
기타 라틴아메리카

제16장 중동 및 아프리카의 시장 분석과 예측

GCC 국가
남아프리카공화국
기타 중동 및 아프리카

제17장 경쟁 구도

시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 : 기업별(2024)
기업 개요
- Viatris Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- Kaleo, Inc.
- ARS Pharmaceuticals, Inc.
- Mylan N.V.
- Glenmark Pharmaceuticals
- Bryn Pharma
- Aquestive Therapeutics, Inc.
- Endo, Inc.
- DMK Pharmaceuticals Corporation
- ALK-Abello A/S
- Amneal Pharmaceuticals LLC
- Grand Pharma(China) Co., Ltd.

KSM

영문 목차

영문목차

Anaphylaxis Market - Scope of Report

TMR's report on the global anaphylaxis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global anaphylaxis market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anaphylaxis market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anaphylaxis market.

Market Snapshot
Market Value in 2024	US$ 2.1 Bn
Market Value in 2035	US$ 3.9 Bn
CAGR	5.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anaphylaxis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anaphylaxis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anaphylaxis market.

The report delves into the competitive landscape of the global anaphylaxis market. Key players operating in the global anaphylaxis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anaphylaxis market profiled in this report.

Key Questions Answered in global anaphylaxis Market Report:

What is the sales/revenue generated by anaphylaxis across all regions during the forecast period?
What are the opportunities in the global anaphylaxis market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Anaphylaxis Market - Research Objectives and Research Approach

The comprehensive report on the global anaphylaxis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anaphylaxis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anaphylaxis market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anaphylaxis Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Anaphylaxis Market Analysis and Forecasts, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Healthcare Expenditure across Key Regions / Countries
5.2. Technological Advancements in Anaphylaxis Management
5.3. Epidemiology of Anaphylaxis across Key Regions / Countries
5.4. Regulatory Scenario across Key Regions / Countries
5.5. PORTER's Five Forces Analysis
5.6. PESTEL Analysis
5.7. Value Chain Analysis
5.8. Key Purchase Metrics for End-users
5.9. Go-to-Market Strategy for New Market Entrants
5.10. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
5.11. Benchmarking of Products Offered by the Leading Competitors

6. Global Anaphylaxis Market Analysis and Forecasts, By Drug Class

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Class, 2020-2035
- 6.3.1. Epinephrine
- 6.3.2. Antihistamines
- 6.3.3. Others
6.4. Market Attractiveness By Drug Class

7. Global Anaphylaxis Market Analysis and Forecasts, By Dosage Form

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Dosage Form, 2020-2035
- 7.3.1. Injectables
- 7.3.2. Tablets / Capsules
- 7.3.3. Others
7.4. Market Attractiveness By Dosage Form

8. Global Anaphylaxis Market Analysis and Forecasts, By Route of Administration

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2020-2035
- 8.3.1. Intramuscular Injection
- 8.3.2. Subcutaneous Injection
- 8.3.3. Oral
- 8.3.4. Others
8.4. Market Attractiveness By Route of Administration

9. Global Anaphylaxis Market Analysis and Forecasts, By Drug Type

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Drug Type, 2020-2035
- 9.3.1. Branded
- 9.3.2. Generic
9.4. Market Attractiveness By Drug Type

10. Global Anaphylaxis Market Analysis and Forecasts, By Distribution Channel

10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Distribution Channel, 2020-2035
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
10.4. Market Attractiveness By Distribution Channel

11. Global Anaphylaxis Market Analysis and Forecasts, By Region

11.1. Key Findings
11.2. Market Value Forecast By Region
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region

12. North America Anaphylaxis Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class, 2020-2035
- 12.2.1. Epinephrine
- 12.2.2. Antihistamines
- 12.2.3. Others
12.3. Market Value Forecast By Dosage Form, 2020-2035
- 12.3.1. Injectables
- 12.3.2. Tablets / Capsules
- 12.3.3. Others
12.4. Market Value Forecast By Route of Administration, 2020-2035
- 12.4.1. Intramuscular Injection
- 12.4.2. Subcutaneous Injection
- 12.4.3. Oral
- 12.4.4. Others
12.5. Market Value Forecast By Drug Type, 2020-2035
- 12.5.1. Branded
- 12.5.2. Generic
12.6. Market Value Forecast By Distribution Channel, 2020-2035
- 12.6.1. Hospital Pharmacies
- 12.6.2. Retail Pharmacies
- 12.6.3. Online Pharmacies
12.7. Market Value Forecast By Country, 2020-2035
- 12.7.1. U.S.
- 12.7.2. Canada
12.8. Market Attractiveness Analysis
- 12.8.1. By Drug Class
- 12.8.2. By Dosage Form
- 12.8.3. By Route of Administration
- 12.8.4. By Drug Type
- 12.8.5. By Distribution Channel
- 12.8.6. By Country

13. Europe Anaphylaxis Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class, 2020-2035
- 13.2.1. Epinephrine
- 13.2.2. Antihistamines
- 13.2.3. Others
13.3. Market Value Forecast By Dosage Form, 2020-2035
- 13.3.1. Injectables
- 13.3.2. Tablets / Capsules
- 13.3.3. Others
13.4. Market Value Forecast By Route of Administration, 2020-2035
- 13.4.1. Intramuscular Injection
- 13.4.2. Subcutaneous Injection
- 13.4.3. Oral
- 13.4.4. Others
13.5. Market Value Forecast By Drug Type, 2020-2035
- 13.5.1. Branded
- 13.5.2. Generic
13.6. Market Value Forecast By Distribution Channel, 2020-2035
- 13.6.1. Hospital Pharmacies
- 13.6.2. Retail Pharmacies
- 13.6.3. Online Pharmacies
13.7. Market Value Forecast By Country / Sub-region, 2020-2035
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Spain
- 13.7.5. Italy
- 13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
- 13.8.1. By Drug Class
- 13.8.2. By Dosage Form
- 13.8.3. By Route of Administration
- 13.8.4. By Drug Type
- 13.8.5. By Distribution Channel
- 13.8.6. By Country / Sub-region

14. Asia Pacific Anaphylaxis Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Drug Class, 2020-2035
- 14.2.1. Epinephrine
- 14.2.2. Antihistamines
- 14.2.3. Others
14.3. Market Value Forecast By Dosage Form, 2020-2035
- 14.3.1. Injectables
- 14.3.2. Tablets / Capsules
- 14.3.3. Others
14.4. Market Value Forecast By Route of Administration, 2020-2035
- 14.4.1. Intramuscular Injection
- 14.4.2. Subcutaneous Injection
- 14.4.3. Oral
- 14.4.4. Others
14.5. Market Value Forecast By Drug Type, 2020-2035
- 14.5.1. Branded
- 14.5.2. Generic
14.6. Market Value Forecast By Distribution Channel, 2020-2035
- 14.6.1. Hospital Pharmacies
- 14.6.2. Retail Pharmacies
- 14.6.3. Online Pharmacies
14.7. Market Value Forecast By Country / Sub-region, 2020-2035
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
- 14.8.1. By Drug Class
- 14.8.2. By Dosage Form
- 14.8.3. By Route of Administration
- 14.8.4. By Drug Type
- 14.8.5. By Distribution Channel
- 14.8.6. By Country / Sub-region

15. Latin America Anaphylaxis Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast By Drug Class, 2020-2035
- 15.2.1. Epinephrine
- 15.2.2. Antihistamines
- 15.2.3. Others
15.3. Market Value Forecast By Dosage Form, 2020-2035
- 15.3.1. Injectables
- 15.3.2. Tablets / Capsules
- 15.3.3. Others
15.4. Market Value Forecast By Route of Administration, 2020-2035
- 15.4.1. Intramuscular Injection
- 15.4.2. Subcutaneous Injection
- 15.4.3. Oral
- 15.4.4. Others
15.5. Market Value Forecast By Drug Type, 2020-2035
- 15.5.1. Branded
- 15.5.2. Generic
15.6. Market Value Forecast By Distribution Channel, 2020-2035
- 15.6.1. Hospital Pharmacies
- 15.6.2. Retail Pharmacies
- 15.6.3. Online Pharmacies
15.7. Market Value Forecast By Country / Sub-region, 2020-2035
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
- 15.8.1. By Drug Class
- 15.8.2. By Dosage Form
- 15.8.3. By Route of Administration
- 15.8.4. By Drug Type
- 15.8.5. By Distribution Channel
- 15.8.6. By Country / Sub-region

16. Middle East & Africa Anaphylaxis Market Analysis and Forecast

16.1. Introduction
- 16.1.1. Key Findings
16.2. Market Value Forecast By Drug Class, 2020-2035
- 16.2.1. Epinephrine
- 16.2.2. Antihistamines
- 16.2.3. Others
16.3. Market Value Forecast By Dosage Form, 2020-2035
- 16.3.1. Injectables
- 16.3.2. Tablets / Capsules
- 16.3.3. Others
16.4. Market Value Forecast By Route of Administration, 2020-2035
- 16.4.1. Intramuscular Injection
- 16.4.2. Subcutaneous Injection
- 16.4.3. Oral
- 16.4.4. Others
16.5. Market Value Forecast By Drug Type, 2020-2035
- 16.5.1. Branded
- 16.5.2. Generic
16.6. Market Value Forecast By Distribution Channel, 2020-2035
- 16.6.1. Hospital Pharmacies
- 16.6.2. Retail Pharmacies
- 16.6.3. Online Pharmacies
16.7. Market Value Forecast By Country / Sub-region, 2020-2035
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
- 16.8.1. By Drug Class
- 16.8.2. By Dosage Form
- 16.8.3. By Route of Administration
- 16.8.4. By Drug Type
- 16.8.5. By Distribution Channel
- 16.8.6. By Country / Sub-region

17. Competition Landscape

17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2024)
17.3. Company Profiles
- 17.3.1. Viatris Inc.
  - 17.3.1.1. Company Overview
  - 17.3.1.2. Financial Overview
  - 17.3.1.3. Product Portfolio
  - 17.3.1.4. Business Strategies
  - 17.3.1.5. Recent Developments
- 17.3.2. Pfizer Inc.
  - 17.3.2.1. Company Overview
  - 17.3.2.2. Financial Overview
  - 17.3.2.3. Product Portfolio
  - 17.3.2.4. Business Strategies
  - 17.3.2.5. Recent Developments
- 17.3.3. Teva Pharmaceutical Industries Ltd.
  - 17.3.3.1. Company Overview
  - 17.3.3.2. Financial Overview
  - 17.3.3.3. Product Portfolio
  - 17.3.3.4. Business Strategies
  - 17.3.3.5. Recent Developments
- 17.3.4. Fresenius Kabi AG
  - 17.3.4.1. Company Overview
  - 17.3.4.2. Financial Overview
  - 17.3.4.3. Product Portfolio
  - 17.3.4.4. Business Strategies
  - 17.3.4.5. Recent Developments
- 17.3.5. Kaleo, Inc.
  - 17.3.5.1. Company Overview
  - 17.3.5.2. Financial Overview
  - 17.3.5.3. Product Portfolio
  - 17.3.5.4. Business Strategies
  - 17.3.5.5. Recent Developments
- 17.3.6. ARS Pharmaceuticals, Inc.
  - 17.3.6.1. Company Overview
  - 17.3.6.2. Financial Overview
  - 17.3.6.3. Product Portfolio
  - 17.3.6.4. Business Strategies
  - 17.3.6.5. Recent Developments
- 17.3.7. Mylan N.V.
  - 17.3.7.1. Company Overview
  - 17.3.7.2. Financial Overview
  - 17.3.7.3. Product Portfolio
  - 17.3.7.4. Business Strategies
  - 17.3.7.5. Recent Developments
- 17.3.8. Glenmark Pharmaceuticals
  - 17.3.8.1. Company Overview
  - 17.3.8.2. Financial Overview
  - 17.3.8.3. Product Portfolio
  - 17.3.8.4. Business Strategies
  - 17.3.8.5. Recent Developments
- 17.3.9. Bryn Pharma
  - 17.3.9.1. Company Overview
  - 17.3.9.2. Financial Overview
  - 17.3.9.3. Product Portfolio
  - 17.3.9.4. Business Strategies
  - 17.3.9.5. Recent Developments
- 17.3.10. Aquestive Therapeutics, Inc.
  - 17.3.10.1. Company Overview
  - 17.3.10.2. Financial Overview
  - 17.3.10.3. Product Portfolio
  - 17.3.10.4. Business Strategies
  - 17.3.10.5. Recent Developments
- 17.3.11. Endo, Inc.
  - 17.3.11.1. Company Overview
  - 17.3.11.2. Financial Overview
  - 17.3.11.3. Product Portfolio
  - 17.3.11.4. Business Strategies
  - 17.3.11.5. Recent Developments
- 17.3.12. DMK Pharmaceuticals Corporation
  - 17.3.12.1. Company Overview
  - 17.3.12.2. Financial Overview
  - 17.3.12.3. Product Portfolio
  - 17.3.12.4. Business Strategies
  - 17.3.12.5. Recent Developments
- 17.3.13. ALK-Abello A/S
  - 17.3.13.1. Company Overview
  - 17.3.13.2. Financial Overview
  - 17.3.13.3. Product Portfolio
  - 17.3.13.4. Business Strategies
  - 17.3.13.5. Recent Developments
- 17.3.14. Amneal Pharmaceuticals LLC
  - 17.3.14.1. Company Overview
  - 17.3.14.2. Financial Overview
  - 17.3.14.3. Product Portfolio
  - 17.3.14.4. Business Strategies
  - 17.3.14.5. Recent Developments
- 17.3.15. Grand Pharma (China) Co., Ltd.
  - 17.3.15.1. Company Overview
  - 17.3.15.2. Financial Overview
  - 17.3.15.3. Product Portfolio
  - 17.3.15.4. Business Strategies
  - 17.3.15.5. Recent Developments